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Patients with the autoimmune rheumatic disease systemic lupus erythematosus (SLE) have multiple defects 
in lymphocyte signaling and function that contribute to disease pathogenesis. Such defects could be attrib-
uted to alterations in metabolic processes, including abnormal control of lipid biosynthesis pathways. Here, 
we reveal that CD4+ T cells from SLE patients displayed an altered profile of lipid raft–associated glycosphin-
golipids (GSLs) compared with that of healthy controls. In particular, lactosylceramide, globotriaosylcera-
mide (Gb3), and monosialotetrahexosylganglioside (GM1) levels were markedly increased. Elevated GSLs in 
SLE patients were associated with increased expression of liver X receptor β (LXRβ), a nuclear receptor that 
controls cellular lipid metabolism and trafficking and influences acquired immune responses. Stimulation 
of CD4+ T cells isolated from healthy donors with synthetic and endogenous LXR agonists promoted GSL 
expression, which was blocked by an LXR antagonist. Increased GSL expression in CD4+ T cells was associ-
ated with intracellular accumulation and accelerated trafficking of GSL, reminiscent of cells from patients 
with glycolipid storage diseases. Inhibition of GSL biosynthesis in vitro with a clinically approved inhibi-
tor (N-butyldeoxynojirimycin) normalized GSL metabolism, corrected CD4+ T cell signaling and functional 
defects, and decreased anti-dsDNA antibody production by autologous B cells in SLE patients. Our data 
demonstrate that lipid metabolism defects contribute to SLE pathogenesis and suggest that targeting GSL 
biosynthesis restores T cell function in SLE.
Introduction
The mechanisms underlying the immunopathogenesis of the auto-
immune rheumatic disease systemic lupus erythematosus (SLE) 
remain uncertain; however, both the disease and its treatment 
result in a substantially increased risk of cardiovascular disease, 
suggesting that a defect in lipid metabolism contributes to the dis-
ease process (1). In support of this concept, patients are character-
ized by dyslipidemia and defects in lymphocyte plasma membrane 
lipid rafts that result in increased cell stimulation (2, 3).
Glycosphingolipids (GSLs) are essential for many cellular pro-
cesses and are composed of a ceramide backbone embedded in 
the outer leaflet of the plasma membrane and a sugar moiety that 
projects into the extracellular space (4). GSLs are enriched predom-
inantly in lipid rafts, regions in the plasma membrane that coordi-
nate the interaction of key signaling molecules that facilitate lym-
phocyte activation and function (2, 5). Furthermore, differential 
GSL expression influences a range of T cell functions including 
TCR-mediated signaling (6–8), apoptosis (9), and recycling and 
endocytosis of membrane signaling and receptor molecules (4).
The control of plasma membrane GSL levels is tightly regu-
lated. De novo biosynthesis is catalyzed by enzymes that promote 
sequential molecular changes from ceramide to generate unique 
GSL categories including globo-, asialo-, and a-series GSLs (Fig-
ure 1A and ref. 10). Vesicular trafficking of newly synthesized lip-
ids to the plasma membrane and subsequent lysosomal and/or 
late endosomal degradation are also integral to the maintenance 
of healthy GSL levels (11). Alterations to these processes can lead 
to a plethora of clinical manifestations, including the lysoso-
mal storage diseases (LSDs) Niemann-Pick type C (NPC), Fabry 
disease, and Gaucher disease (12). However, very little is known 
about the effect of altered GSL expression on T cell function in 
human health and autoimmunity.
CD4+ T cells from SLE patients are characterized by many abnor-
malities including: increased levels of raft-associated GSLs and 
cholesterol; defects in the lipid raft location and function of key 
TCR signaling molecules; accelerated recycling of TCR-associated 
proteins; and increased cell death and defects in mitochondrial 
function and autophagy (2, 3, 13). Given that GSLs mediate many 
of these cellular processes (4, 12), it is possible that changes in GSL 
expression could contribute to SLE pathogenesis. Intriguingly, 
manipulation of membrane lipids by in vitro culture with ator-
vastatin (known to reduce cholesterol biosynthesis) can normalize 
membrane GM1 expression, phosphorylation of LCK and ERK, 
and production of IL-10 and IL-6 in T cells from SLE patients (14). 
This effect suggests that targeting membrane lipids could control 
or alter immune cell activation and may be an important therapeu-
tic approach for autoimmune disease.
Here, we show that CD4+ T cells from SLE patients had a dis-
rupted GSL profile that was associated with accelerated GSL 
trafficking and accumulation in intracellular compartments. 
We found that elevated GSL expression could be recapitulated in 
healthy T cells by in vitro stimulation with synthetic (GW3965) or 
potential endogenous liver X receptor β (LXRβ) agonists (oxidized 
LDL and serum), suggesting that T cell defects in SLE patients 
could be driven, in part, by dyslipidemia. Inhibition of GSL expres-
sion in vitro using the clinically approved inhibitor N-butyldeoxy-
nojirimycin (NB-DNJ) (15) modified GSL metabolism and T cell 
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function to resemble that observed in T cells from healthy donors. 
Thus, our findings suggest that defects in lipid metabolism con-
tribute to the immunopathogenesis of SLE and that targeting 
lipid biosynthesis pathways could be a novel therapeutic strategy 
for the treatment of SLE.
Results
Dysregulated GSL expression in CD4+ T cells from patients with SLE. Our 
recent findings show that changes in the composition and organi-
zation of lipids in the plasma membrane can influence T cell func-
tion (16). In order to characterize total T cell GSL composition, lip-
Figure 1
Altered GSL profile in T cells from patients with SLE. (A) Scheme showing GSL biosynthesis pathways, indicating some of the enzymes con-
trolling biosynthesis. Cellular lipids were isolated from negatively selected CD4+ T cells from 40 SLE patients and 15 healthy donors by chloro-
form-methanol extraction. The total cellular GSL profile was analyzed by HPLC following glycanase digestion to release the GSL sugar head 
groups. (B) Representative qualitative HPLC plots showing the position of known GSL standards and GSL species in 1 healthy control and 2 
SLE patients. (C) Cumulative quantitative data for each GSL species identified on the HPLC plots. GSL expression was calculated from the peak 
HPLC areas after applying an experimentally derived response factor (18) by relating the area of the HPLC peak to the cell number of the sample. 
Two-tailed Mann-Whitney U test; **P = 0.008; *P ≤ 0.05. Expression of surface GSL was determined in ex vivo PBMCs from 58 SLE patients, 
36 healthy donors, and 10 patients with OADs (Sjögren’s syndrome and RA). Cells were stained using fluorescently labeled antibodies against 
CD4-v450, LC-PE-Cy5, Gb3-FITC, or CTB-FITC and analyzed by flow cytometry. (D) Representative flow cytometric dot plots showing staining 
with appropriate controls (percentage of CD4+GSLhi  T cells and GSL MFI of total CD4+ T cells is shown). Cumulative data of percentage of 
CD4+GSLhi T cells (E) and GSL MFI in total CD4+ T cells (F). One-way ANOVA; *P ≤ 0.05; **P ≤ 0.007; ***P = 0.0006.
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ids were extracted from negatively isolated CD4+ T cells from SLE 
patients and healthy donors and analyzed by HPLC (ref. 17 and Fig-
ure 1B). Quantitative analysis of the HPLC plots revealed (18) that 
T cells from SLE patients had a profoundly altered GSL profile, 
with a significantly increased expression of lactosylceramide (LC), 
GA2, Gb3, GM2, GD1a, and GM1 compared with that of T cells 
from healthy donors (Figure 1C). This represented an increase in 
several different GSL species (including globo-, a-, and asiolo-series) 
when assessed according to their position in the GSL biosynthesis 
pathway (Supplemental Figure 1A; supplemental material available 
online with this article; doi:10.1172/JCI69571DS1).
We determined GSL expression in CD4+ T cell plasma mem-
branes by flow cytometry using the available GSL-specific anti-
bodies. We found that expression of LC, Gb3 (using anti-CD77 
antibody but also binding to Shiga toxin B; data not shown), 
and GM1 (binding to cholera toxin B [CTB]) was substantially 
increased in CD4+ T cells from SLE patients compared with that 
in cells from healthy donors and from patients with other auto-
immune disease (OAD) (Figure 1, D–F). We observed no change 
in the expression of GM3 or GM2 (data not shown). Culture of 
T cells from healthy donors with a potent inhibitor of GSL synthe-
sis (D-PDMP) decreased cell-surface GSL expression, confirming 
specificity of the anti-GSL antibodies (Supplemental Figure 1B).
Interestingly, we found that expression of GM1 was low in all sam-
ples, as measured by HPLC, compared with its detection by CTB 
binding and flow cytometry. This has been observed previously and 
is attributed to CTB binding to related structures including GM3 
and GM2 (T. Butters, unpublished observations and ref. 19). In light 
of this finding, we continued to use CTB binding as a surrogate 
marker of GSL expression rather than a specific marker for GM1.
GSL expression was not influenced by disease activity, as assessed by 
the British Isles Lupus Assessment Group (BILAG) global score (Sup-
plemental Figure 1C), or by treatment with prednisolone or hydroxy-
chloroquine (Supplemental Figure 1, D and E). Since hydroxychloro-
quine is known to affect lipid homeostasis (20), we cultured healthy 
T cells with this drug for 72 hours at a concentration equivalent to 
that detected in vivo, but did not observe an effect on plasma mem-
brane LC, CTB, or Gb3 expression (Supplemental Figure 1F).
Thus, we show that GSL expression in both total cellular and 
plasma membrane compartments was profoundly altered in ex 
Figure 2
Increased GSL expression is associated with defective GSL homeostasis in T cells from SLE patients. PBMCs from 8 healthy donors and 8 SLE 
patients were stimulated for 24 and 72 hours with or without 1 μM GW3965 (GW). Cells were stained for CD4-APC and CTB-FITC or LC-FITC. 
Representative flow cytometric plots for (A) CTB binding and (B) LC expression after a 24- and 72-hour culture and (C) cumulative data. MO, 
medium only. One-way ANOVA, *P ≤ 0.05; 2-tailed Student’s t test, **P ≤ 0.003. RNA extracted from negatively isolated CD4+ T cells from 10 SLE 
patients and 6 healthy controls was assessed by qPCR for the expression of LXRB, LXRA, NPC1, NPC2, ABCA1, ABCG1, and SREBP2 genes. 
(D) Cumulative results are shown in relative units comparing the gene of interest with a GAPDH control. Two-tailed Student’s t test; *P ≤ 0.05; 
**P ≤ 0.001. Ex vivo PBMCs from 13 SLE patients and 6 healthy donors were surface stained for CD4-APC followed by intracellular staining for 
LXRβ before analysis by flow cytometry. (E) Cumulative data show the mean. Two-tailed Student’s t test; **P = 0.007.
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vivo CD4+ T cells from patients with SLE compared with that seen 
in healthy donors and disease controls.
Increased GSL expression is associated with defective GSL homeostasis in 
T cells from SLE patients. Increased GSL expression is associated with 
T cell activation (2, 21). We confirmed this observation in T cells 
from healthy donors; however, an analysis of GSL expression in 
functional CD4+ T cell subsets revealed that increased GSL expres-
sion was not restricted to activated T cells in SLE patients (Supple-
mental Figure 2, A–E). The association between cell activation and 
increased GSL expression was further confirmed when we either 
rested (no stimulation) or TCR stimulated CD4+ T cells in vitro. 
In contrast to our observation that T cells from healthy donors 
upregulated CTB binding and LC and Gb3 expression in response 
to TCR stimulation, T cells from patients with SLE had a dysregu-
lated pattern of GSL expression in both resting and TCR-activated 
cells (Supplemental Figure 2F). Further, we detected no evident 
changes in GM3 expression levels (data not shown). Together, 
these results suggest that T cell activation was not solely responsi-
ble for the increased GSL expression we observed in patients.
GSL expression can be driven by mechanisms other than TCR 
stimulation. GSLs are derived from ceramide (Figure 1A), whose 
production is mediated by proinflammatory cytokines and an 
altered serum lipid environment, among other stimuli (22). We 
tested whether these stimuli translated into increased GSL expres-
sion in CD4+ T cells from healthy donors by stimulating cells with 
TNF-α and IL-6, which are significantly increased in the serum 
of SLE patients (Supplemental Figure 3A and ref. 1), or with syn-
thetic agonists of nuclear receptors that regulate cellular lipid 
homeostasis, such as liver X receptor (LXR) (GW3965) and PPARγ 
(23). Surprisingly, we found that stimulation with recombinant 
human TNF-α (rhTNF-α), IL-6, and PPARγ agonist had an insig-
nificant effect on GSL expression (Supplemental Figure 3B and 
data not shown). In contrast, GW3965 stimulation significantly 
increased LC expression and CTB binding in CD4+ T cells from 
healthy donors after a 24-hour culture (Figure 2, A–C). We found 
that this effect was transient, with LC expression and CTB binding 
returning to ex vivo levels by 72 hours, suggesting that GSL expres-
sion was strictly controlled. In contrast, CD4+ T cells from SLE 
patients displayed a sustained increased expression of GSL after 
GW3965 stimulation for 72 hours (Figure 2, A–C).
A role for LXR in defective CD4+ T cell GSL homeostasis was 
supported by our finding that LXRB and its target genes NPC1 
and NPC2, but not ABCA1 or ABCG1, were upregulated in ex vivo 
CD4+ T cells from SLE patients compared with those from healthy 
donors, as assessed by quantitative PCR (qPCR) (Figure 2D). We 
found that SREBP2, a gene that can indirectly affect LXR expression 
Figure 3
Upregulation of LXRβ by oxysterol and TCR stimulation. (A) CD4+ T cells from 3 healthy donors and 3 SLE patients were cultured for 18 
hours with GW3965 or CM and analyzed by Western blotting for LXRβ expression. (B) Cumulative data. Paired and 2-tailed Student’s t test; 
*P ≤ 0.05. (C) CD4+ T cells from 5 healthy donors and 5 SLE patients cultured for 18 hours with GW3965 or CM were assessed by qPCR for 
LXRB expression. Cumulative results comparing LXRB with GAPDH control. Paired and 2-tailed Student’s t tests; *P ≤ 0.05. PBMCs from 
a healthy donor were cultured for 72 hours (all plus IL-2) with serum from 5 heterologous healthy donors (HC serum), 5 SLE patients (SLE 
serum), or with CM only (MO). (D) Cumulative data. One-way ANOVA; *P = 0.05. (E) CD4+ T cells from 5 healthy donors were cultured for 72 
hours with LDL, oxidized LDL (oxLDL), or CM before CTB staining. Representative histograms and cumulative data. One-way ANOVA; *P ≤ 0.01. 
(F) PBMCs from a healthy donor were cultured with serum from 12 healthy donors, 12 SLE patients, or with CM (all plus IL-2) (for 72 hours and 
for 10 days) and stained with CTB. Cumulative data showing percentage change from CM. One-way ANOVA; *P ≤ 0.05. (G) PBMCs from 4 SLE 
patients and 4 healthy donors were cultured for 3 days with GW3965 ± the LXR antagonist 5CPPSS-50 and stained with CTB. One-way ANOVA; 
*P ≤ 0.05. (H) PBMCs from a healthy donor were cultured for 10 days as described in F with serum from 4 SLE patients ± 5CPPSS-50 and 
stained with CTB. One-way ANOVA; *P = 0.03.
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(24), was also upregulated in T cells from SLE patients. Increased 
LXRB expression was associated with significantly increased LXRβ 
protein levels, as assessed by flow cytometry (Figure 2E) and West-
ern blotting (Figure 3, A and B). We detected no significant change 
in the levels of glycolipid synthase enzymes (shown in Figure 1A), 
including glucosylceramide synthase, GM3 synthase, and Gb3 syn-
thase (data not shown).
LXRβ expression in CD4+ T cells is upregulated by oxysterol and TCR stimu-
lation. Most work examining the function of LXRβ has been described 
in macrophages, where it is known to be stimulated by increased cel-
lular or serum oxysterols (25). To ascertain whether this was also the 
case in CD4+ T cells, we stimulated them with the synthetic oxysterol 
agonist GW3965. GW3965 activation increased LXRβ protein and 
gene expression levels in T cells from both healthy donors and SLE 
patients (Figure 3, A–C). This effect was recapitulated by culture 
with serum from SLE patients (as a potential source of endogenous 
oxysterols) compared with cells cultured with serum from healthy 
individuals or with medium alone (Figure 3D). Furthermore, we 
observed that culture with oxidized LDL or extended culture with 
serum from SLE patients increased GSL expression in CD4+ T cells 
from healthy donors (Figure 3, E and F). This suggests that chronic 
stimulation by potential endogenous LXR agonists in the serum of 
SLE patients could contribute to increased T cell GSL biosynthesis.
TCR stimulation also increases GSL expression (refs. 2, 21, and 
Supplemental Figure 2F), and we found that in vitro TCR stimu-
lation significantly upregulated LXRβ gene and protein expression 
in both healthy and SLE patients (Supplemental Figure 3, C and 
D, and data not shown).
Finally, to confirm that oxysterol and TCR stimulation of 
LXRβ influenced GSL expression, we costimulated CD4+ T cells 
from SLE patients and healthy donors with an LXR antagonist 
(5-chloro-N-2′-n-penthylphenyl-1,3-dithiophthalimide, 5CPPSS-
50) (2, 26). 5CPPSS-50 blocked LXRβ upregulation in response to 
GW3965 and SLE serum (Supplemental Figure 3, E and F), but 
had only an insignificant effect following TCR stimulation (data 
not shown). Similarly, 5CPPSS-50 reversed increased GSL expres-
sion in response to GW3965 and SLE serum, but not TCR stimu-
lation (Figure 3, G and H, and data not shown).
Together, these results support the hypothesis that increased 
GSL expression in T cells from SLE patients is driven, in part, by 
Figure 4
Increased recycling of GSLs in T cells from SLE patients. CD4+ T cells from 6 SLE patients and 6 healthy donors were incubated with Bodipy-LC 
on ice, then washed and cultured for up to 30 minutes at 37°C to allow endocytosis before analysis by confocal microscopy and flow cytometry. 
(A) Representative confocal microscopy images of Bodipy-LC at 1 and 30 minutes. Bodipy-LC was excited at 450 to 490 nm and viewed at 520 
to 560 nm (green) or >590 nm (red). Scale bars: 5 μM. (B) Quantitative flow cytometric data showing Bodipy-LC emissions at 520 to 560 nm (left) 
and >590 nm (right). Paired Student’s t test, *P = 0.05 and **P = 0.005; 2-tailed Student’s t test, ***P ≤ 0.05. (C) Experiment in B was repeated ± 
dynasore to inhibit endocytosis. Representative histograms. (D) CD4+ T cells from 5 healthy donors and 5 SLE patients were labeled with CTB-
FITC. Cells were washed and incubated at 37°C for 1, 3, or 5 minutes to allow endocytosis of CTB-stained lipids. Cells were washed in neutral 
or acidic PBS, and lipid internalization was calculated as a ratio of the two. As a control, cells were preincubated with dynasore (dyn). Two-tailed 
Student’s t test; *P = 0.04; ***P = 0.0005. (E) Surface GSLs on CD4+ T cells from 5 healthy donors and 5 SLE patients were blocked with uncon-
jugated CTB and  incubated at 37°C for 5, 10, and 15 minutes. Newly recycled GSLs were detected by surface staining with CTB-FITC and flow 
cytometry. Two-tailed Student’s t test; *P = 0.03.
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LXRβ stimulation via altered serum lipids and T cell activation. 
They also suggest that the homeostatic mechanisms controlling 
balanced GSL expression levels were dysregulated in CD4+ T cells 
from SLE patients, resulting in an accumulation of cellular GSL.
GSL recycling and turnover is altered in T cells from SLE patients com-
pared with those from healthy controls. Stimulation of LXR is known 
to directly control expression of NPC1 and NPC2 proteins, 
which regulate cellular GSL transport and recycling (27). Since 
expression of these genes was also increased in CD4+ T cells from 
patients with SLE (Figure 2D), we investigated whether abnormal 
GSL trafficking contributed to their increased surface expression 
in SLE patients. We used a fluorescently labeled exogenous probe, 
Bodipy-LC, which emits fluorescence at differential wavelengths 
depending on its cellular location (520–560 nm [green] when 
incorporated into the plasma membrane and cytosol or >590 nm 
[red] when concentrated into intracellular compartments includ-
ing endosomes or lysosomes) (28). At baseline, T cells from SLE 
patients had incorporated significantly more Bodipy-LC into 
both the plasma membrane and cytosol (green fluorescence) and 
intracellular compartments (red fluorescence) compared with 
healthy controls (1-minute time point Figure 4A, left panels, and 
Figure 4B). After 30 minutes, T cells from SLE patients retained 
higher levels of Bodipy-LC, whereas these levels were significantly 
reduced in T cells from healthy controls (Figure 4A, right pan-
Figure 5
Increased LAMP1 expression and altered lipid colocalization to functionally normal lysosomes in SLE CD4+ T cells. (A) PBMCs from 11 healthy 
donors and 11 SLE patients were surface stained for CD4-APC before fixing, permeabilizing, and staining for intracellular LAMP1-PE (CD107a-
PE). Representative dot plots and cumulative data. Two-tailed Student’s t test; ****P = 0.00001. (B–E) CD4+ T cells from 6 SLE patients and 3 
healthy donors were fixed and permeabilized before staining for LAMP1 and either CTB (B) or LC (D) and analyzed by confocal microscopy. Scale 
bars: 5 μM (insets show  ×2.5 enlargement). Colocalization of LAMP1-CTB (C) or LAMP1-LC (E) assessed by Pearson’s colocalization coefficient 
(Rr). Cumulative data. Two-tailed Student’s t test, *P = 0.05. (F) PBMCs from 10 SLE patients were labeled with CD4-APC and incubated with 
LysoSensor Green DND before flow cytometric analysis. Results were correlated with LAMP1 expression measured in F. R2 = 0.4754; *P ≤ 0.05.
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els, and Figure 4B). Although T cells from SLE patients incorpo-
rated and retained significantly more Bodipy-LC than those from 
healthy donors, the rate of reduction of this probe  in the plasma 
membrane, cytosol, and intracellular compartments was compara-
ble over time (Supplemental Figure 4A).
We found that the uptake of Bodipy-LC was an active process, 
since inhibition of clathrin-independent endocytosis (known to 
be responsible for GSL internalization; ref. 28) using the dynamin 
inhibitor dynasore or the Src kinase inhibitor PP2 inhibited the 
probe’s uptake and reduced its incorporation into intracellular 
compartments (Figure 4C and data not shown, respectively).
We next investigated both the internalization of endogenous 
GSLs from the plasma membrane into intracellular compart-
ments and their recycling from intracellular compartments back 
to the plasma membrane. We observed that GSL internalization 
was prompt in CD4+ T cells from both healthy donors and SLE 
patients. However, we found that GSL internalization was signifi-
cantly more rapid at the 3- and 5-minute time points in T cells 
from SLE patients compared with those from healthy donors (Fig-
ure 4D and data not shown for LC).
Recycling of GSLs back to the plasma membrane was also rapid 
in T cells from both SLE patients and healthy donors. However, we 
observed that GSL recycling was more sustained over a 15-minute 
time course in T cells from SLE patients than in those from healthy 
donors in whom GSL recycling declined over time (Figure 4E 
and data not shown for LC).
Thus, elevated cellular GSL levels were associated with acceler-
ated and sustained GSL internalization and recycling dynamics in 
CD4+ T cells from SLE patients, leading to a net increase in plasma 
membrane expression.
Increased retention of cellular GSLs in CD4+ T cells from SLE patients. 
Since cellular GSL expression levels are controlled by lysosomal 
and/or late endosomal degradation (11), we investigated whether 
GSL degradation was also defective in T cells from SLE patients 
compared with those from healthy donors. First, we observed 
that the expression of the lysosomal marker lysosomal-associated 
membrane protein 1 (LAMP1) was significantly increased in T cells 
from SLE patients compared with those from controls (Figure 5A).
We confirmed by confocal microscopy that expression of LAMP1, 
LC, and CTB binding was elevated in T cells from SLE patients (Fig-
ure 5, B and D). We observed that CTB distribution was more clus-
tered in T cells from patients compared with those from healthy 
and mirrored the pattern of LAMP1 distribution. This was associ-
ated with increased CTB and LAMP1 colocalization in SLE patients 
compared with that observed in healthy donors (Figure 5, B and C). 
We detected no differences in LC or LAMP1 colocalization (Figure 
5, D and E); however, the overall levels of colocalization between 
GSLs and LAMP1 were low in the T cells from both healthy donors 
and SLE patients (Figure 5, C and E). On close examination, the 
distribution pattern for GSLs and LAMP1 suggested subcompart-
mentalization of the lyso somes between protein-rich (LAMP1) and 
lipid-rich (CTB/LC) regions (Figure 5, B and D, enlarged insets). 
Figure 6
Inhibition of GSL biosynthesis modifies GSL recycling in T cells from SLE patients. (A) PBMCs from 24 SLE patients and 11 healthy donors were 
TCR stimulated for 72 hours with or without 10 μM NB-DNJ. Cells were surface stained using fluorescently labeled antibodies against CD4-v450, 
LC-PE-Cy5, or CTB-FITC and assessed by flow cytometry. Cumulative data showing expression of CTB and LC. Two-tailed Student’s t test; 
*P ≤ 0.05. (B) CD4+ T cells from 5 SLE patients and 5 healthy donors were cultured for 72 hours with or without NB-DNJ. Internalization of endoge-
nous GSLs after a 5-minute incubation was assessed as described in Figure 4D. Cumulative data showing the effect of NB-DNJ treatment on CTB 
internalization. Two-tailed Student’s t test; *P ≤ 0.05. CD4+ T cells from 3 SLE patients and 3 healthy donors were cultured for 72 hours with or with-
out NB-DNJ. Uptake of Bodipy-LC was assessed as described in Figure 4, A and B. (C) Line graphs showing uptake of Bodipy-LC by flow cytometry. 
Paired Student’s t-test for SLE samples; *P ≤ 0.01. (D) Representative confocal images showing merged green and red Bodipy-LC accumulation in 
T cells after a 30-minute incubation. Scale bars: 5 μM. (E) CD4+ T cells isolated from 4 patients with SLE were cultured for 72 hours with or without 
NB-DNJ. Cells were surface stained for CD4-APC and intracellularly stained for LAMP1-PE. Paired Student’s t test; *P ≤ 0.05.
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Figure 7
NB-DNJ modifies TCR-associated defects in T cells from patients with SLE. PBMCs from 5 SLE patients and 5 healthy donors were cultured 
for 7 days with NB-DNJ. Cells were labeled with anti-CD3/CD28 (1 μg/ml) and cross-linking anti-mouse IgG on ice before culturing at 37°C for 
1 and 5 minutes. Cells were fixed and labeled with fluorescent barcoding reagents and stained for CD4-APC and intracellularly stained for the 
phosphorylated signaling proteins pTCR-ζ, pERK, pAKT, and pNF-κB. (A) Cumulative results from three separate experiments. Two-tailed Stu-
dent’s t test; *P ≤ 0.05 or paired t test; **P = 0.001. PBMCs from 24 SLE patients and 11 healthy donors were TCR stimulated for 72 hours with 
anti-CD3/CD28 (1 μg/ml) with or without 10 μM NB-DNJ. Cell culture supernatants were collected. Cells were surface stained with CD4-v450 
and intracellularly stained for Ki67-PE and assessed by flow cytometry. (B) Representative flow cytometric dot plots (C) and cumulative results 
showing Ki67 expression as the percentage change from unstimulated controls. Two-tailed Student’s t test; *P ≤ 0.05. Cell culture supernatants 
from 12 SLE patients and 10 healthy donors collected from B were analyzed by CBA. Representative CBA plots (D) and cumulative data (E) are 
shown. Two-tailed Student’s t test and paired t test; *P ≤ 0.05. (F) CD4+ T cells isolated from 4 SLE patients were pretreated with NB-DNJ, then 
cocultured with autologous B cells for 7 days in the presence of anti-CD3 (1 μg/ml). The production of anti-dsDNA antibodies was detected by 
ELISA. Paired Student’s t test; *P ≥ 0.05.
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No significant differences were noted in early endosome antigen 1 
expression or colocalization with LC or CTB in T cells from healthy 
donors and SLE patients (Supplemental Figure 4, B–D).
We tested whether lysosomes in T cells from SLE patients were 
defective and unable to process excess levels of intracellular GSLs. 
Using a probe to detect lysosomal acidity (LysoSensor Green 
DND-189), we found a significant positive correlation between 
LAMP1 and LysoSensor staining in T cells from SLE patients, sug-
gesting that although the lysosomes were increased in number, 
they were functionally normal (in terms of acidity) (Figure 5F).
Therefore, the results imply that the normal mechanisms con-
trolling GSL expression were overwhelmed by increased GSL bio-
synthesis in T cells from SLE patients. This culminated in acceler-
ated GSL trafficking and the accumulation of GSLs in the plasma 
membrane and intracellular compartments, despite apparently 
normal lysosome function.
Inhibition of GSL biosynthesis reduced GSL expression and trafficking 
in CD4+ T cells from patients with SLE. GSL accumulation, which 
interferes with GSL trafficking and lysosomal degradation, is 
also a feature of patients with LSDs (12). Blocking GSL synthe-
sis using specific inhibitors, including NB-DNJ (a reversible com-
petitive inhibitor of glucosylceramide synthase; ref. 29), rectifies 
defective GSL homeostasis and is used therapeutically in patients 
(15). Therefore, we assessed the in vitro effect of NB-DNJ on 
T cells from SLE patients. Culture for 72 hours in the presence 
of NB-DNJ diminished TCR-induced upregulation of CTB bind-
ing and LC and GB3 expression in T cells from SLE patients to 
the levels observed in T cells from healthy donors (Figure 6A and 
data not shown for GB3). This was accompanied by a significantly 
reduced rate of internalization of endogenous GSL (Figure 6B and 
data not shown for LC) and reduced uptake of exogenous Bodipy- 
LC by T cells from SLE patients (Figure 6C). Furthermore, culture 
with NB-DNJ altered the intracellular distribution of internalized 
Bodipy-LC in T cells from SLE patients in a pattern that we con-
sistently observed in T cells from healthy donors (Figure 6D) and 
was associated with a reduced expression of LAMP1 in T cells from 
SLE patients (Figure 6E).
NB-DNJ moderated TCR-associated defects in T cells from patients with 
SLE. Since culture with NB-DNJ was able to restore a healthy pat-
tern of GSL expression and trafficking in T cells from patients with 
SLE, we assessed whether it could also reverse some of the in vitro 
lipid raft–associated defects associated with these T cells (2, 3). 
We cultured PBMCs with and without NB-DNJ (10 μM) for 
7 days to ensure that endogenous GSL levels were reduced. We 
then stimulated CD4+ T cells with anti-CD3/28 antibodies and 
used flow cytometry to measure the phosphorylation of key sig-
naling molecules. As described previously, signaling molecule 
phosphorylation patterns are altered in T cells from SLE patients 
compared with those from healthy donors (2, 3). However, we 
found that TCR-mediated phosphorylation of TCR-ζ, ERK, and 
NF-κB was partially restored in NB-DNJ–treated T cells from SLE 
patients, while we detected no significant effect on AKT phospho-
rylation (Figure 7A). The gating strategy for the analysis is shown 
in Supplemental Figure 5, A and B.
As expected, moderation of T cell signaling by NB-DNJ was 
associated with the partial normalization of some T cell func-
tions. This included reduced proliferation, as measured by Ki67 
expression (Figure 7, B and C) and thymidine incorporation (Sup-
plemental Figure 5C), and altered regulation of IL-6, IL-10, and 
TNF-α production (Figure 7, D and E). In addition, we observed 
Figure 8
Proposed model for altered GSL expression and 
metabolism in CD4+ T cells from SLE patients. We 
propose that several components of SLE pathol-
ogy, including dyslipidemia and T cell hyperactivity 
(i), elicit upregulation of the nuclear receptor LXRβ, 
and hence its downstream target genes NPC1 and 
NPC2 (ii). Enhanced activation of LXRβ induces 
increased de novo GSL biosynthesis (iii). CD4+ T 
cells from SLE patients are characterized by accel-
erated GSL trafficking and accumulation of GSL in 
the plasma membrane (iv) and intracellular compart-
ments (v), despite higher levels of functionally nor-
mal lysosomes (vi). Inhibition of GSL biosynthesis 
with NB-DNJ reduced cellular GSL levels and mod-
ified cell function in CD4+ T cells from SLE patients 
(vii). TGN, trans-Golgi network.
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acterized by increased recycling of TCR-associated molecules, 
including CD4 and CTLA-4, which affects their activation and 
inhibitory functions, respectively (37).
Therefore, an altered plasma membrane GSL profile could influ-
ence the balance between positive and negative signals transduced 
during activation and contribute to the characteristic T cell dys-
function seen in SLE patients. This proposition is supported by 
work showing that in vitro cross-linking of GSLs elicits different 
functional responses in CD4+ T cells from healthy donors compared 
with those from SLE patients (E. Jury, unpublished observations). 
The presence of anti-GSL antibodies in the serum of a small per-
centage of SLE patients has been reported previously (38). However, 
anti-GSL antibodies were not detected in our patient cohort (E. Jury, 
unpublished observations). Nevertheless, it remains uncertain how 
differential GSL expression alters T cell function in vivo, although 
it seems likely that GSLs play an essential role in modifying signals 
transduced via TCR and costimulatory molecule activation.
Our results imply that more than one factor influences increased 
GSL levels in patients. In addition to TCR stimulation, activation 
of lipid biosynthesis pathways using an LXR agonist induced a sus-
tained increase in GSL levels in CD4+ T cells from SLE patients, but 
not in T cells from healthy controls. This was associated with an 
increased ex vivo expression of LXRβ, but not LXRα, and some LXRβ 
target genes in T cells from SLE patients. To date, little is known 
about the interaction between TCR-stimulation and lipid homeo-
stasis. Tontonoz et al. showed that TCR stimulation downregulates 
some LXRβ target genes involved in cholesterol efflux (39). Crucially, 
this suggests that the functional capacity of immune cells can be reg-
ulated by mechanisms controlling lipid homeostasis (25, 39).
The results of our study point to an unrecognized function for 
LXRβ stimulation in the control of T cell GSL expression. Contrary 
to previous reports examining LXRβ expression in macrophages, 
we found that GW3965 and oxLDL stimulation upregulated LXRβ 
protein and mRNA expression in human T cells (Figure 3 and ref. 
40). Since differences in LXR stimulation exist between human and 
murine macrophages and between different cell types (41), this 
upregulation could possibly be due to an unrecognized human 
T cell–specific LXR enhancer. However, we cannot rule out a role for 
LXRα in lipid-mediated T cell function, although no difference in ex 
vivo (Figure 2D) or GW3965-stimulated LXRα expression (data not 
shown) was found in T cells from healthy donors and SLE patients.
Since levels of cellular cholesterol and GSL are closely associated 
(12, 42), it seems likely that alterations in cholesterol homeosta-
sis could also contribute to changes in GSL expression in T cells 
from SLE patients. Two primary features of LSDs are an aberrant 
trafficking of GSLs coupled with cholesterol accumulation and an 
inability of lysosomes to degrade excess glycolipids (12). A similar 
phenotype is observed in T cells from SLE patients, since choles-
terol measured by filipin binding is also elevated (2). Interestingly, 
SREBP2 was upregulated in ex vivo T cells from SLE patients. 
SREBP2 activates cholesterol synthesis, indirectly activates LXR, 
and can transactivate NPC1/2 genes (24, 43). Thus, it is clear that 
more work is needed to fully understand the complex interactions 
in human T cells that occur between LXRβ, SREBP2, and associ-
ated target genes to maintain GSL homeostasis, lipid raft stability, 
and lipid raft function in health and autoimmunity.
The exact nature of the potential LXR agonists present in the 
serum or cells of patients needs to be determined. Dyslipidemia is 
common in SLE patients, and several studies have reported reduced 
levels of HDL, increased levels of triglycerides, and increased LDL 
that apoptosis, as measured by annexin V binding, was reduced 
(data not shown).
Finally, we found that NB-DNJ reduced the capacity of T cells 
from SLE patients to drive anti-dsDNA antibody production by 
autologous B cells (Figure 7F). Thus, we show that NB-DNJ, a suc-
cessful, clinically approved therapy for LSDs, could rectify some of 
the defects associated with abnormal T cell function in SLE patients.
Discussion
We report a number of findings in support of our hypothesis that 
alterations in the control of lipid metabolism underlie abnormal 
T cell function in patients with SLE. First, we demonstrate a pro-
found alteration in the GSL profile of T cells from SLE patients. 
Second, we show that defects in GSL biosynthesis were driven, in 
part, by stimulation of the lipid-responsive nuclear receptor LXRβ. 
Finally, we reveal that NB-DNJ, a successful, clinically approved 
therapy for patients with LSDs, normalized GSL expression and 
rectified some of the signaling and functional abnormalities char-
acteristic of T cells from SLE patients. A scheme outlining the pro-
posed mechanism for altered GSL expression in T cells from SLE 
patients is shown in Figure 8.
The consequences of GSL accumulation have been studied exten-
sively in experimental models and in patients with LSDs. These 
diseases result from mutations in single proteins involved in the 
control of GSL trafficking or metabolism (12). Patients are charac-
terized by severe neurological, renal, and cardiac deficiencies attrib-
uted to GSL accumulation in organs and tissues as well as by multi-
ple immunological defects (30). Unlike most of the inherited LSDs, 
which are characterized by the accumulation of a specific class of 
GSL, we found that the accumulation of GSLs in CD4+ T cells from 
SLE patients was not restricted to a specific GSL species and that 
the precise GSL profile varied between patients. This observation 
suggests that the increased GSL expression was not associated with 
a specific defect in synthase enzyme expression or activity. However, 
although we did not detect any significant change in the expression 
of key GSL synthase enzymes by Western blot analysis, this does 
not rule out the possibility of a defect in enzyme activity or in one 
of the other enzymes that control GSL expression (31).
There is a growing appreciation that GSL heterogeneity con-
tributes to membrane protein compartmentalization in resting 
and activated T cells. Within T cells, the distribution of GSLs is 
heterogeneous; for example, GM1 and GM3 are distributed asym-
metrically toward the leading edge or the uropod of T cells, respec-
tively (32). The essential proximal TCR signaling molecules LCK 
and LAT reside in different lipid raft subsets that fuse upon TCR 
stimulation (33), and the interaction of TCR-associated signaling 
molecules (including LCK, LFA1, and PI3K) with GM3 or GM1 
induces differential recruitment of downstream signaling targets 
that affect T cell function (34, 35). Moreover, recent reports show 
that CD4+ and CD8+T cells exclusively require a-series and o-series 
GSLs, respectively, for TCR-mediated activation (8, 36). The reduc-
tion of cellular GSL levels by pharmacological means or by disrup-
tion of GM3 synthase activity can inhibit the differentiation of 
CD4+ T cells into Th17 cells (7) and reduce cytokine production in 
activated T cells during viral infection (31).
We also observed accelerated GSL recycling and a substantial 
accumulation of intracellular GSLs in T cells from SLE patients. 
A consequence of increased GSL trafficking could be an acceler-
ated recycling of cell surface proteins that affect cell activation 
(4, 12). Importantly, ex vivo T cells from SLE patients are char-
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qPCR
RNA was extracted from CD4+ T cells with TRIzol (Invitrogen) according 
to the manufacturer’s instructions. Sample concentration and purity were 
determined by spectrophotometric analysis. RT-PCR and qPCR were per-
formed using primers for LXRB, NPC1, NPC2, ABCA1, ABCG1, SREBP2, and 
the housekeeping gene GAPDH (QIAGEN).
Cell cultures
T cell activation. PBMCs or CD4+ T cells were cultured in complete medium 
(CM) (RPMI 1640 containing L-glutamine and NaHCO3 [Sigma-Aldrich] 
with 10% FCS [Lonza], and 100 U/μg/ml penicillin-streptomycin 
[Sigma-Aldrich] at 37°C in 5% CO2); 1 μg/ml anti-CD3 (HIT-3A); and 
1 μg/ml anti-CD28 (CD28.2) (eBioscience). Cells were cultured as 
above with or without GSL biosynthesis inhibitors (100 μM D-PDMP; 
Sigma-Aldrich or 10 μM NB-DNJ).
LXR agonist experiments. PBMCs were cultured in CM with or without 
1 μM GW3965 (Sigma Aldrich) for 24 hours and 72 hours.
Serum experiments. PBMCs were cultured in CM or RPMI and 10% serum 
from SLE patients or healthy donors plus IL-2 (0.5 ng/ml) for 24 hours, 
3 days, 7 days, or 10 days. The CM was replenished every 3 days.
Antagonist experiments. PBMCs or CD4+ T cells were cultured with 1 μM 
GW3965, anti-CD3/28 (each at 1 μg/ml), or serum from SLE patients or 
healthy donors with or without an LXR antagonist (10 μM 5C PPSS-50; 
Wako) for 24 and 72 hours in CM.
T and B cell cocultures. PBMCs were cultured with or without 10 μM 
NB-DNJ in CM for 24 hours. CD4+ T cells were then negatively isolated and 
resuspended in CM with autologous B cells negatively isolated from a freshly 
thawed aliquot. T and B cells were cocultured for 7 days with or without 
anti-CD3/CD28 (1 μg/ml each) and with or without NB-DNJ (10 μM). 
Supernatants were removed on day 7 and analyzed by ELISA (Euro Diag-
nostica) for the presence of anti-IgG dsDNA antibodies.
Flow cytometry
All surface stains were performed in 1% FCS and 0.01% sodium azide in PBS 
on ice. All data were collected on an LSRII (BD) and analyzed with FlowJo 
software (Tree Star Inc.).
GSL expression. PBMCs were stained with either CTB-FITC (Sigma-Aldrich), 
LC-PE-cyano dye 5 (Cy5), LC-FITC (LifeSpan Biosciences Inc.), or CD77-FITC 
(Gb3-FITC), followed by CD4-APC or CD4-BD Horizon V450 (BD Biosciences).
Assessment of Ki67, LAMP1 (CD107a), and LXRβ expression. Cells were surface 
stained for 60 minutes before fixation and permeabilization (Fix/Perm Buf-
fer; eBioscience) then stained intracellularly with anti-Ki67–PE (BD Biosci-
ences), anti–CD107a-PE (eBioscience), or purified rabbit anti-human LXRβ 
IgG (Abcam), followed by anti-rabbit IgG FITC (Sigma-Aldrich). In addition, 
the appropriate isotype or fluorescence-minus-one controls were used.
Detection of phosphorylated signaling proteins and fluorescent barcoding. 
PBMCs from SLE patients and healthy donors were stimulated and 
labeled with fluorescent cell barcoding dye according to the manufactur-
er’s instructions (BD Biosciences). The procedure is described in detail  in 
the Supplemental Methods.
Lysosomal pH analysis. PBMCs were surface stained with CD4-APC (BD 
Biosciences), washed, and resuspended in LysoSensor Green DND-153 
(Molecular Probes) for 30 minutes at 37°C in 5% CO2.
Measurement of GSL trafficking
Internalization of Bodipy-LC. CD4+ T cells from SLE patients and healthy 
donors were either labeled ex vivo, cultured overnight in CM with or with-
out 10 μM NB-DNJ, or preincubated with 50 μM dynasore (Invitrogen) 
or 50 μM Src kinase inhibitor PP2 (Calbiochem). Samples were incubated 
with 10 μg/ml Bodipy-LC (Invitrogen) on ice for 30 minutes, then at 37°C 
oxidation, which can be associated with increased disease activity 
and proinflammatory cytokine production (1, 44). Thus, it seems 
likely that defects in GSL expression in SLE patients could be 
driven by serum dyslipidemia. Indeed, many patients included in 
the present study had altered lipid levels (Supplemental Table 1).
The ability of inhibitors of GSL biosynthesis to restore defects in 
lipid (GSL and cholesterol) homeostasis and to inhibit T cell pro-
liferation, cytokine production, and differentiation has been iden-
tified previously in cell lines and animal models (7, 45). We found 
that NB-DNJ treatment of CD4+ T cells from patients with SLE 
modified their T cell function in response to in vitro TCR stim-
ulation (Figure 7). Critically, this was achieved by reducing GSL 
levels and modifying GSL recycling and accumulation, effects also 
seen in cells from patients with LSDs who were treated with GSL 
reduction therapies (12, 46). Interestingly, we found that NB-DNJ 
increased TNF-α production in T cells from SLE patients, but 
decreased its production in T cells from healthy donors. The role 
of TNF-α in human SLE is controversial; it can cause tissue dam-
age via its proinflammatory activity or be beneficial by dampening 
autoimmune responses. Such heterogeneity of effect could be due 
to changes in membrane lipids that influence immune cell func-
tion (5). Blocking TNF-α therapeutically has not been accepted in 
clinical practice (47). There are several precedents for the thera-
peutic control of lipids, examples of which include HIV infection 
(48), cancer (49), and atherosclerosis (50). Thus, a growing body 
of evidence supports the hypothesis that correct cellular lipid 
metabolism regulates the capacity of T cells to correctly respond 
to microenvironmental stimuli and that therapeutic targeting of 
such molecules could influence immune cell activation and help 
regulate abnormal immune responses in autoimmunity.
In summary, we provide evidence of a profound dysregulation in 
both cellular and surface GSL expression in CD4+ T cells from SLE 
patients. This dysregulation was due to increased GSL biosynthe-
sis driven, at least in part, by serum dyslipidemia and T cell hyper-
activity in SLE patients. Abnormal GSL levels and a range of func-
tional cellular defects were rectified by targeting GSL biosynthesis 
with a clinically approved inhibitor. Our findings reveal a role for 
defects in lipid metabolism in SLE pathogenesis and highlight 
what we believe to be a novel treatment strategy for the disease.
Methods
Patients and controls
Peripheral blood was obtained from SLE patients attending the lupus clinic 
at University College Hospital (London, United Kingdom). Supplemental 
Table 1 provides a summary of the healthy donors included in this study as 
well as the treatments and clinical characteristics of the SLE patients.
PBMC and CD4+ T cell isolation
PBMCs were isolated from heparinized blood using Ficoll-Paque PLUS (GE 
Healthcare) gradient centrifugation. PBMCs (107 cells/ml) were resuspended 
in FCS (Biosera) and 10% DMSO (Sigma-Aldrich) and frozen until use. CD4+ 
T cells were isolated by negative selection (MACS; Miltenyi Biotec).
Lipid extraction, GSL glycan labeling, and HPLC analysis
Lipids were extracted from CD4+ T cells (107 cells) using chloroform:metha-
nol (v/v). Following ceramide glycanase cleavage of the glycan head groups, 
glycans were labeled with anthranilic acid and analyzed by normal phase- 
HPLC, as previously described (25). The detailed procedure for GSL glycan 
labeling and HPLC analysis is described in the Supplemental Methods.
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using a 2-tailed Student’s t test, a paired Student’s t test, or 1-way ANOVA 
as specified. P values less than 0.05 were considered significant. Data were 
tested for normal distribution using the Kolmogorov-Smirnov test with 
GraphPad Prism software.
Study approval
Ethical approval (00/0241, 11/H0808/19) was obtained for this study from 
the ethics committee of the University College London Hospitals National 
Health Service Trust (London, United Kingdom). All participating patients 
and healthy donors provided written informed consent.
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Analysis of cell culture supernatants
Detection of cytokines from purified CD4+ T cell culture supernatants 
was performed by cytokine bead array (CBA) analysis (BD Bioscience) 
according to the manufacturer’s instructions. Samples were analyzed on 
a FACSArray Bioanalyzer (BD).
Quantitative immunoblots
CD4+ T cells (107 cells) were lysed and analyzed by Western blotting using 
mouse anti-LXRβ (Abcam) or anti-actin mAb (Sigma-Aldrich). Adobe Photo-
shop was used for quantification of the protein bands (Adobe Systems Inc.).
Confocal microscopy
CD4+ T cells were fixed, permeabilized, and blocked before staining for 
lysosomes (anti-LAMP1 IgG1 and anti-IgG1 Alexa 555), early endosomes 
(anti-EEA1 IgG and anti-IgG-Alexa 633), and either anti-LC IgM and anti-
IgM Alexa Fluor 488 or CTB-FITC. Detailed microscopy procedures are 
described in the Supplemental Methods.
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